Our results strongly suggest that siRNA RET/PTC3-SQ NPs could be accredited as a potential new pharmacological approach for papillary thyroid carcinoma with RET/PTC3 junction oncogene. This evidence concerns the gene RET and thyroid gland papillary carcinoma.